Replimune Group (REPL)
(Real Time Quote from BATS)
$10.40 USD
-0.06 (-0.57%)
Updated Sep 17, 2024 10:34 AM ET
3-Hold of 5 3
D Value F Growth A Momentum D VGM
Brokerage Reports
0 items in cart
Replimune Group, Inc. [REPL]
Reports for Purchase
Showing records 21 - 40 ( 201 total )
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Fiscal Q1 Financials; CERPASS Delayed 1 Quarter but Strong IGNYTE Data
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
RP1 Collaboration Agreement Inked With Incyte; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
RP1 ARTACUS Initial Trial Results Appear Favorable; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
ARTACUS Update: Promising Durable CRs for Monotherapy RP1 in SOT Patients
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
RP1 and RP2 Data at ASCO; FY2023 Financials; Modulating PT to $51
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
ASCO 2023 Abstract Roundup for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Fiscal Q4 Financials; CERPASS Topline in 3Q:23; IGNYTE ASCO Update
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
As The Dust Settles -- Sifting Through The Biotech Carnage, We See Opportunity
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Fiscal Q3 Financials; CERPASS Topline Pushed to Q3:23
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
F3Q23 Financials Reported; Adjusting PT Up to $50
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
RP1 Data Update; Collaboration Inked With Roche For RP3; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
RP1 IGNYTE Melanoma Data on Fire; RP2/3 Robust Ph 2 Development Plan Confirmed
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R